QI
EBS icon

Quotient Investors’s Emergent Biosolutions EBS Stock Holding History

Quotient Investors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,400
Closed -$211K – 233
2015
Q2 		$211K Buy
+6,400
New +$198K 0.03% 225

Other funds holding EBS

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quotient Investors's EBS Position: Q3 2015 in Review

Quotient Investors sold out of Emergent Biosolutions (EBS) in Q3 2015, closing a stake of 6,400 shares — an estimated $211K sold.

Quotient Investors first reported a position in EBS in Q2 2015 and held it in 1 quarter. The position peaked at $211K in Q2 2015. 199 funds tracked by Wall St. Rank hold EBS as of Q3 2015.

  • Quotient Investors reported no remaining Emergent Biosolutions position as of Q3 2015 after selling out during the quarter.
  • Quotient Investors sold 6,400 Emergent Biosolutions shares in Q3 2015, an estimated $211K.
  • Quotient Investors first reported a position in Emergent Biosolutions in Q2 2015 and held it in 1 quarter.
  • Quotient Investors's Emergent Biosolutions position peaked at $211K in Q2 2015.
  • 199 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2015.

Based on Quotient Investors's 13F filing for Q3 2015, filed 21 Oct 2015.